Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) traded down 5.2% during mid-day trading on Thursday . The stock traded as low as $3.06 and last traded at $3.10, with a volume of 101,524 shares. The stock had previously closed at $3.27.

Several equities research analysts recently issued reports on the stock. Zacks Investment Research downgraded shares of Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, May 5th. Canaccord Genuity reaffirmed a “buy” rating on shares of Aurinia Pharmaceuticals in a research note on Thursday, May 12th. HC Wainwright assumed coverage on shares of Aurinia Pharmaceuticals in a research note on Thursday, June 30th. They set a “buy” rating and a $7.00 price target on the stock. Finally, Leerink Swann reaffirmed an “outperform” rating and set a $7.00 price target on shares of Aurinia Pharmaceuticals in a research note on Wednesday. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $7.15.

The company’s market capitalization is $100.09 million. The firm has a 50 day moving average of $2.76 and a 200-day moving average of $2.59.

Aurinia Pharmaceuticals Inc (Aurinia) is a Canada-based is a clinical stage pharmaceutical company. The Company is focused on the development of its therapeutic immunomodulating drug candidate, voclosporin, which is a calcineurin inhibitor (CNI). Voclosporin is an oral drug, administered twice daily.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.